Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bioage Labs's book value per share for the quarter that ended in Jun. 2026 was €7.11.
During the past 12 months, Bioage Labs's average Book Value Per Share Growth Rate was -0.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.
Bioage Labs's current price is €8.755. Its book value per share for the quarter that ended in Jun. 2026 was €7.11. Hence, today's PB Ratio of Bioage Labs is 1.23.
During the past 4 years, the highest P/B Ratio of Bioage Labs was 3.06. The lowest was 0.38. And the median was 1.26.
Bioage Labs (HAM:Y7G) Book Value per Share Explanation
Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.
For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.
Bioage Labs Book Value per Share Related Terms
Bioage Labs Book Value per Share Historical Data
* Premium members only.
The historical data trend for Bioage Labs's Book Value per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:Y7G vs PCRX, ALVO, AMPH: Book Value per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bioage Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bioage Labs PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bioage Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bioage Labs's PB Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bioage Labs (HAM:Y7G) has a Book Value per Share of €7.11 as of Jun. 2026. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Bioage Labs and its competitors.
Is Bioage Labs' Book Value per Share too high?
Bioage Labs' current Book Value per Share is €7.11. Overall, Bioage Labs has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Bioage Labs' Book Value per Share compare to PCRX and ALVO?
Bioage Labs' Book Value per Share of €7.11 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Bioage Labs and its competitors. Bioage Labs's current Book Value per Share is €7.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bioage Labs stock overvalued right now?
Bioage Labs (HAM:Y7G) has a current Book Value per Share of €7.11. The current Book Value per Share is €7.11. Bioage Labs' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Bioage Labs (HAM:Y7G), the current Book Value per Share is €7.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
20GF Score
Get the complete analysis for HAM:Y7G
Book Value per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:Y7G has been successfully added to your 
